🎯
LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.

$ANAB
AnaptysBio, Inc.
FREE PREVIEW
AVG HISTORICAL GAP5.22%
MAX GAP RECORD18.60%
PREMIUM
AI ACCURACY RATE92.4%
Unlock AI Insights 🔓LAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $ANAB
EXECUTIONS2 LOGS
WIN RATE••.•%
NET ROI+•••.••%
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| 2026-09-01 | QUANT ALGO | SELL x5 | $•••.•• → $•••.•• | 1228m | 🔒 ENCRYPTED | -16.64% |
| ••••-••-•• | 🔒 LOCKED | ••• x• | $•••.•• → $•••.•• | ••h ••m | 🔒 LOCKED | +••.••% |
🔒 Institutional Data Protected
UNLOCK FULL BLOTTERExact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
AVG VOLATILITY7.1%
Bullish Gaps
Bearish Gaps
Neutral
Intelligence Brief
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic… Read full dossier
CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL